Clinical Trials in Entebbe, Uganda
1 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,580 enrolled27 locationsNCT07071623
Recruiting
Phase 3
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
HIV Infections
ViiV Healthcare3,508 enrolled34 locationsNCT06134362